Neurocrine Biosciences | Операционный Доход



Operating Profit Изменить Дата
AbbVie USD -1490000000 5.32B 2024-12
Acadia Pharmaceuticals USD 153.5M 121.86M 2024-12
Agios Pharmaceuticals USD -125037000 1.11B 2024-12
ALKERMES USD 162.69M 57.93M 2024-12
Alnylam Pharmaceuticals USD -105159000 28.25M 2024-12
Amgen USD 2.31B 182M 2024-12
Biogen USD 441.4M 24.4M 2024-12
BioMarin Pharmaceutical USD 161.41M 47.51M 2024-12
Cytokinetics USD -139040000 1.76M 2024-12
Dynavax Technologies USD -1632000 11.71M 2024-12
Exelixis USD 163.21M 27.13M 2025-01
Gilead Sciences USD 2.45B 1.56B 2024-12
Halozyme Therapeutics USD 175.5M 12.3M 2024-12
Incyte USD 301.51M 155.43M 2024-12
Ionis Pharmaceuticals USD -110823000 37.83M 2024-12
Neurocrine Biosciences USD 142M 41.8M 2024-12
Pfizer USD -409000000 5.57B 2024-12
Prothena USD -64897000 1.62M 2024-12
Regeneron Pharmaceuticals USD 990.2M 189.3M 2024-12
Repligen USD -7830000 10.29M 2024-09
Sarepta Therapeutics USD 161.68M 139.48M 2024-12
Teva Pharmaceutical Industries USD 455M 506M 2024-12
Ultragenyx Pharmaceutical USD -122278000 9.71M 2024-12
Vertex Pharmaceuticals USD 1.03B 90.3M 2024-12



Neurocrine Biosciences Операционный Доход - Текущие значения, предыдущие значения, прогнозы, графики и экономический календарь - Apr 2025.